All News

The breakthrough therapy designation was based on preliminary activity reported in the phase 2 RUN-HN clinical trial, which evaluated tipifarnib in patients with recurrent or metastatic HRAS-mutant head and neck squamous cell carcinoma.

A study published in The Lancet Hematology found an increased risk of developing myelodysplastic syndrome and acute myeloid leukemia when patients with cancer were treated with PARP inhibitors compared with placebo.

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed how she hopes the results of the KEYNOTE-799 study will impact testing going forward.

Richard Schilsky, MD, touched on the research driving ASCO to award “Advance of the Year” to molecular profiling in gastrointestinal cancers, and what the organization’s top priorities are in the near future.

According to investigators on the CheckMate 9LA trial, these data support the use of nivolumab plus ipilimumab and 2 cycles of chemotherapy as a new first-line treatment for patients with advanced non–small cell lung cancer, regardless of PD-L1 expression or histology.

The results of a study on telehealth give insight into both the potential barriers and possible benefits of these services, which have been widely utilized since the start of the COVID-19 pandemic.

The sNDA submission for ruxolitinib to treat steroid-refractory chronic graft-versus-host disease in adult and pediatric patients 12 years and older was based on the phase 3 REACH3 study, which is assessing the safety and efficacy of ruxolitinib compared with best available therapy.

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed the adverse events associated with the use of pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non–small cell lung cancer.

Celsion Corporation announced that fast track designation was granted to their immunotherapy, GEN-1, to treat patients with advanced stage III or IV ovarian cancer.

The approval of cemiplimab in non–small cell lung cancer was supported by results from the phase 3 EMPOWER-Lung 1 trial that investigated its use as monotherapy in the first-line setting compared with platinum-doublet chemotherapy in patients with locally advanced or metastatic disease whose tumor cells expressed PD-L1.

Continued approval for durvalumab in previously treated adult patients with locally advanced or metastatic bladder cancer was dependent upon results from the phase 3 DANUBE trial in the first-line metastatic bladder cancer setting, which did not meet its primary end points in 2020.

Follow-up data published in the European Association of Urology did not find a significant improvement in overall survival for patients with locally advanced renal cell carcinoma undergoing adjuvant pazopanib treatment.

A Q-TWiST analysis evaluated the use of tivozanib versus sorafenib among patients with advanced renal cell carcinoma included in the phase 3 TIVO-3 study.

Investigators compared lenvatinib plus either pembrolizumab or everolimus versus sunitinib in patients with advanced renal cell carcinoma in the CLEAR trial.

Investigators suggested that a new model could be used to identify service gaps at the population level after adjusting to the important local variations in cancer epidemiology.

An expert discusses how new data from the phase 3 CheckMate 9ER trial impact therapy choice in previously untreated advanced renal cell carcinoma.

Patients with advanced lung cancer whose tumors harbor an NTRK gene fusion with or without central nervous system metastases were found to have high response rates, durable responses, and extended survival benefit with larotrectinib.

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey spoke about the possible implications of the KEYNOTE-799 study findings.

“Patients from socially vulnerable communities had the most difficulty achieving a postoperative course without a complication, and they were the most likely to have an extended length of stay. These patients are in double and triple jeopardy,” said senior author Timothy Pawlik, MD.

Data published in Patient Preference and Adherence found communication improved between patients with CLL and their oncologists when the risk of adverse events and patient goals were top of mind.

Findings presented at the 2021 Transplant & Cellular Therapy Meetings indicate that patients with B-cell non-Hodgkin lymphoma may benefit from a type of natural killer immunotherapy added to chemotherapy and transplant.

These phase 3 study results support the use of sequential chemoradiation as a preferred adjuvant treatment following radical hysterectomy for patients with early-stage cervical cancer.

The medical oncologist and physician scientist based at the University of Texas MD Anderson Cancer Center explained recommendations for SARS-CoV-2 vaccination in patients participating in phase 1 oncology clinical trials.

A retrospective, population-based cohort study in JAMA Oncology found Black women in the United States were more likely to have a high-risk recurrence score and die of axillary node-negative breast cancer than non-Hispanic White women who had similar scores.

A CASI press release detailed data from a phase 1/2a study examining BI-1206 in combination with rituximab to treat patients with non-Hodgkin lymphoma.

The biologics license application is for the locally administered fusion protein Vicineum for the treatment of high-risk, bacillus Calmette-Guérin (BCG)–unresponsive non-muscle invasive bladder cancer.

A promising approach to treating newly diagnosed acute graft-versus-host disease emerges, based on data regarding the use of the humanized IgG1 monoclonal antibody itolizumab.

The CLEAR trial compared treatment with lenvatinib plus either pembrolizumab or everolimus versus sunitinib in patients with advanced renal cell carcinoma.

In the OlympiA trial, patients with high-risk HER2-negative breast cancer were randomized 1:1 to receive either olaparib or placebo for 12 months.

A supplemental new drug application submission was primarily based on safety and efficacy data from the global phase 3 ASPEN trial of zanubrutinib compared with ibrutinib for the treatment of Waldenström macroglobulinemia.